Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M

FEMASYS INC

2024-Q3 EPS reported -$0.62 revenue$1,047,532

Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales recorded.
Net loss $5.4M ($0.24/share) vs $4.0M ($0.26) in Q3 2023; cash $7.6M.
Cash runway expected into July 2025 based on current operating plan.
Partnerships with Boston IVF, Spain distributors; FDA clearance for FemChec; CE Mark for FemVue MINI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.